Clinical Trials Network Mid-Atlantic Collaborative Group

临床试验网络中大西洋合作小组

• 批准号: 8531894
• 负责人: ROBERT P SCHWARTZ
• 金额: $ 113.45万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8531894
• 关键词: Adolescent; Adoption; Adult; Ancillary Study; Area; Baltimore; Buprenorphine; Caring; Clinic; Clinical; Clinical Services; Clinical Trials; Clinical Trials Network; Cognitive; Collaborations; Communities; Criminal Justice; Decision Making; Development; District of Columbia; Drug Addiction; Drug abuse; Drug usage; Drug user; Effectiveness; Emergency Medicine; Enrollment; Evidence based practice; Faculty; Fertilization; Friends; Funding; Future; Genetic Research; Goals; Grant; HIV; Health Personnel; Incentives; Institutes; Intervention; Leadership; Marijuana; Maryland; Mental disorders; Mission; Multi-Institutional Clinical Trial; National Institute of Drug Abuse; Nature; Organizational Affiliation; Paper; Participant; Pharmaceutical Preparations; Positioning Attribute; Primary Health Care; Process; Productivity; Protocols documentation; Provider; Publications; Publishing; Quality of Care; Recording of previous events; Recovery; Relative (related person); Reporting; Research; Research Infrastructure; Research Institute; Research Personnel; Research Support; Research Training; School Dentistry; Science; Services; Site; Testing; Translational Research; Universities; Virginia; Vision; Walkers; Women' s Health; base; behavioral health; clinical practice; community based treatment; community setting; contingency management; dissemination research; effective therapy; experience; high risk sexual behavior; improved; medical schools; meetings; motivational enhancement therapy; primary care setting; programs; public health relevance; research in practice; research to practice; treatment program

DESCRIPTION (provided by applicant): The Mid Atlantic Node was among the first participants in the National Drug Abuse Treatment Clinical Trials Network. It's Regional Research and Training Center (RRTC) is comprised of distinguished faculty from Johns Hopkins University School of Medicine, Virginia Commonwealth University and Friends Research Institute as well as directors of affiliated community treatment programs (CTP's). This partnership between researchers and clinical service providers has been functioning effectively over the past 10 years and has allowed the Node to make substantial contributions to the CTN including leadership of two studies, and participation in 7 additional studies with 601 subjects enrolled during the last 5-year funding period. Importantly, the Node has an outstanding record of publication productivity with 24 publications reporting on CTN main study findings, ancillary studies and secondary analyses and supports the Chair of the CTN Publications Committee. In the upcoming grant period, the Node will maintain collaboration with VCU while expanding its affiliation with Friends Research Institute. This will bring additional faculty expertise and infrastructure support into the Node including expertise in medications development (e.g. Frank Vocci) and criminal justice research (Timothy Kinlock). We have formed broader affiliations at VCU with the Women's Health Institute (Susan Kornstein), the Institute for Drug Addiction Science (Robert Balster) and the Institute for Genetics Research (Kenneth Kendler). At Johns Hopkins, we have expanded faculty affiliates to bring in additional expertise in clinical trials, contingency management, cognitive testing, and marijuana research. We have established affiliations with the Hopkins Department of Emergency Medicine, with the School of Dentistry at University of Maryland and with the Johns Hopkins Institute for Clinical Translational Research (ICTR). Finally, we have added CTP's, including the Whitman Walker Clinic in Washington DC, that incorporate primary care, HIV care and co-occurring mental health disorders in their scope of service and a new clinic (Richmond Behavioral Health) with extensive experience in community participatory research. All these new affiliations will help the Node to meet short- and long-term expansion in the mission of CTN and to participate in a wide variety of studies that are likely to be developed. Finally, the Node will continue its strong dissemination activities that provide significant benefit to affiliated CTP's while promoting adoption of evidence-based practices.

描述（由申请人提供）：大西洋中部节点是国家药物滥用治疗临床试验网络的首批参与者之一。它的区域研究和培训中心（RRTC）由来自约翰霍普金斯大学医学院，弗吉尼亚联邦大学和朋友研究所的杰出教师以及附属社区治疗计划（CTP）的董事组成。研究人员和临床服务提供商之间的这种伙伴关系在过去10年中一直有效运作，并使该节点为CTN做出了重大贡献，包括领导两项研究，并参与了另外7项研究，在过去5年的资助期间招募了601名受试者。重要的是，该节点在出版生产力方面有着出色的记录，有24篇出版物报告了CTN的主要研究结果、辅助研究和次要分析，并支持CTN出版委员会主席。在即将到来的赠款期间，节点将保持与VCU的合作，同时扩大与朋友研究所的联系。这将带来额外的教师专业知识和基础设施支持到节点，包括药物开发（例如弗兰克Vocci）和刑事司法研究（蒂莫西金洛克）的专业知识。我们在VCU与妇女健康研究所（Susan Kornstein），药物成瘾科学研究所（Robert Balster）和遗传学研究所（Kenneth Kendler）建立了更广泛的联系。在约翰霍普金斯，我们已经扩大了教师附属机构，带来了临床试验，应急管理，认知测试和大麻研究的额外专业知识。我们与霍普金斯急诊医学部、马里兰州大学牙科学院和约翰霍普金斯临床转化研究所（ICTR）建立了联系。最后，我们增加了CTP，包括华盛顿特区的惠特曼步行者诊所，该诊所将初级保健、艾滋病毒护理和共同发生的精神健康障碍纳入其服务范围，以及一个在社区参与性研究方面具有丰富经验的新诊所（里士满行为健康）。所有这些新的联系将有助于该节点满足CTN使命的短期和长期扩展，并参与可能开发的各种研究。最后，该节点将继续开展强有力的传播活动，为附属现金转拨方案提供重大惠益，同时促进采用循证做法。